The Association of the British Pharmaceutical Industry (ABPI) have responded to the publication of new research by pressure group Change Britain.
The research reports that the EU Clinical Trials Directive has "delayed lifesaving medical research ... costing both lives and money" and that by operating outside of the single market "we can stop these damaging EU regulations and spend the billions we send to Brussels each year on our priorities like the NHS ."
Responding, Dr Virginia Acha, ABPI's Executive Director – Research, Medical & Innovation said:
"The UK is a global hub for research and development in healthcare, and as one of the go-to destinations for clinical trials in Europe, heeding this advice would be a backwards step for medical science and patients in the UK.
If we look at the evidence, the latest data shows the UK is becoming increasingly competitive in clinical research. As part of the current EU regulatory system, we lead the delivery of phase one clinical trials in Europe and rank second for the delivery of phase two and phase three trials.
With the new EU Clinical Trials Regulations only set to speed-up efficiency and enhance collaboration, and as the global pharmaceutical industry takes the fight to diseases that affect smaller and smaller patient populations, cooperation and alignment with this network will be the best way to ensure the provision of innovative, novel treatments for UK patients. Going it alone is not the best option."
### ENDS ###
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.